Interview: Dr. Philippe Douville, President and CEO, Milestone Pharmaceuticals,…
Dr. Douville talks investment, the company’s role in R&D in Canada and their plans for some of their…
Milestone Pharmaceutical
Last updated: 13.02.2014
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics based on clinically validated mechanisms. Milestone’s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as supraventricular tachycardia and angina.
Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $17 million in venture capital financing since 2006.
At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs.
Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.
6100 Royalmount Avenue
Montreal, (Quebec)
H4P 2R2 Canada
Telephone: (514) 496-3220
Fax: (514) 496-3219
Interviews
Related
Canada / Concrete Steps Toward National Pharmacare
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific…
Canada / Federal Consultations on a National Strategy for Rare Disease Drugs
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
Canada / The Evolution of Medical Cannabis Legislation
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
Canada / Has the Time Truly Come for Trudeau’s ‘National Pharmacare’?
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
Canada / Pharma News Roundup September 2020
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
Pricing / Drugmakers Push Back Against Canada's New Regulations
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory…
Alzheimer's / Canadian-Led Innovation Post-Aducanumab
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
Canada / Global Pharma has Reinvented R&D: Will Canadian Start-Ups Lead the Next Phase?
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Opinion / A New Approach to Rare Diseases in Canada
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to…
Pharma Faces / Marina Vasiliou, Biogen Canada
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…
Canada / Collective Impact in the Health Charity Sector
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to…
Patents: A Key Factor in Winning the Cannabis Arms Race
A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial…
